Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.63M | 10.93M | 16.92M | 16.89M | 9.73M |
| Total Other Revenue | 989.10K | 1.02M | 1.32M | 1.32M | 958.10K |
| Total Revenue | 11.61M | 11.94M | 18.25M | 18.21M | 10.69M |
| Cost of Revenue | 996.70K | 1.02M | 1.74M | 1.74M | 796.10K |
| Gross Profit | 10.62M | 10.92M | 16.50M | 16.47M | 9.89M |
| SG&A Expenses | 4.19M | 4.31M | 4.55M | 4.54M | 4.93M |
| Depreciation & Amortization | 198.00K | 203.60K | 186.80K | 186.40K | 187.50K |
| Other Operating Expenses | -- | -- | -185.50K | -185.10K | -- |
| Total Operating Expenses | 6.31M | 6.49M | 6.82M | 6.81M | 6.16M |
| Operating Income | 5.30M | 5.45M | 11.42M | 11.40M | 4.53M |
| Income Before Tax | 7.15M | 7.35M | 11.82M | 11.80M | 4.82M |
| Income Tax Expenses | 2.56M | 2.63M | 3.68M | 3.67M | 1.26M |
| Earnings from Continuing Operations | 4.59M | 4.72M | 8.14M | 8.12M | 3.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.59M | 4.72M | 8.14M | 8.12M | 3.56M |
| EBIT | 5.30M | 5.45M | 11.42M | 11.40M | 4.53M |
| EBITDA | 5.50M | 5.66M | 11.48M | 11.46M | 4.72M |
| EPS Basic | 0.09 | 0.09 | 0.16 | 0.16 | 0.07 |
| Normalized Basic EPS | 0.09 | 0.09 | 0.15 | 0.15 | 0.06 |
| EPS Diluted | 0.09 | 0.09 | 0.16 | 0.16 | 0.07 |
| Normalized Diluted EPS | 0.09 | 0.09 | 0.15 | 0.15 | 0.06 |
| Average Basic Shares Outstanding | 50.07M | 50.07M | 50.12M | 50.12M | 49.55M |
| Average Diluted Shares Outstanding | 50.27M | 50.27M | 50.47M | 50.47M | 51.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 17.79% | 17.79% | 0.00% | 0.00% | 22.59% |